Recent progress in pediatric lymphoblastic leukemia

Abstract

The probability of long-term survival for children with lymphoblastic leukemia has improved dramatically over recent decades, mainly owing to advances in genomic analysis techniques, which have improved our understanding of the nature of leukemic cells and prognostic prediction based on the evaluation of precise treatment response. Risk-adjusted chemotherapy based on these advances has simultaneously reduced relapse rates and minimized complications. In addition, recent genomic analyses have deepened our understanding of the pathogenesis of leukemia and revealed the involvement of germline variations in the clinical course of leukemia treatment. Additionally, advances in minimal residual disease assays and the introduction of immunotherapy are expected to further improve therapeutic analyses. Further advances in clinical and translational research are anticipated to improve survival to 100% in a healthy state.

Thrombin Generation Profile Using ST-Genesia after PEG-asparaginase in Pediatric Patients with Acute Lymphoblastic Leukemia

“…Intensive chemotherapy protocols have led to improved survival of pediatric acute lymphoblastic leukemia (ALL). 1 However, this has been also accompanied by a variety of relevant side effects such as venous thromboembolism (VTE), 2 which has been related to higher morbidity and mortality rates, 3,4 and a significantly worse overall survival and event-free survival compared with patients without VTE. 5 However, although VTE is a potentially preventable complication, there is still a lack of robust evidence to recommend routine thromboprophylaxis in this setting.…”